These findings not only reinforce the pivotal role of the miR-8072/TFAP2A axis in the suppression of TNBC, but also highlight its potential as a promising therapeutic target for this aggressive subtype of breast cancer. This evidence concerns the gene TFAP2A and breast carcinoma.